Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation
Author:
Affiliation:
1. The Zena and Michael A. Wiener Cardiovascular Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, USA
Publisher
Informa UK Limited
Subject
Cardiology and Cardiovascular Medicine,General Medicine,Internal Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14779072.2018.1523718
Reference79 articles.
1. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
2. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
3. DAPT Duration After DES
4. Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration
5. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations;Molecular Therapy;2022-10
2. Prognostic and Practical Validation of ESC/EACTS High Ischemic Risk Definition on Long-Term Thrombotic and Bleeding Events in Contemporary PCI Patients;Journal of Atherosclerosis and Thrombosis;2021
3. Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis;Diabetes Therapy;2020-08-25
4. Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI;BMC Cardiovascular Disorders;2020-07-01
5. Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline;Cardiovascular Drugs and Therapy;2020-06-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3